FY2020 EPS Estimates for C.R. Bard Inc. Decreased by Leerink Swann (BCR)
C.R. Bard Inc. (NYSE:BCR) – Equities researchers at Leerink Swann dropped their FY2020 EPS estimates for C.R. Bard in a research note issued on Friday. Leerink Swann analyst R. Newitter now forecasts that the brokerage will earn $14.00 per share for the year, down from their previous estimate of $14.02. Leerink Swann currently has a “Market Perform” rating and a $233.00 target price on the stock.
A number of other equities research analysts have also recently commented on BCR. Bank of America Corp. cut C.R. Bard from a “buy” rating to a “neutral” rating in a research note on Friday, July 8th. Barclays PLC lifted their price objective on C.R. Bard from $224.00 to $235.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 27th. Deutsche Bank AG lifted their price objective on C.R. Bard from $234.00 to $240.00 and gave the stock a “hold” rating in a research note on Wednesday, July 27th. Citigroup Inc. lifted their price objective on C.R. Bard from $241.00 to $265.00 and gave the stock a “buy” rating in a research note on Wednesday, July 27th. Finally, Jefferies Group lifted their target price on C.R. Bard from $215.00 to $237.00 and gave the stock a “hold” rating in a report on Wednesday, July 27th. Thirteen equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. C.R. Bard presently has a consensus rating of “Hold” and a consensus price target of $233.00.
Shares of C.R. Bard (NYSE:BCR) opened at 219.80 on Monday. The firm has a 50-day moving average price of $222.32 and a 200 day moving average price of $220.76. C.R. Bard has a 12-month low of $172.21 and a 12-month high of $239.43. The stock has a market cap of $16.15 billion, a PE ratio of 51.12 and a beta of 0.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/fy2020-eps-estimates-for-c-r-bard-inc-decreased-by-leerink-swann-bcr.html
C.R. Bard (NYSE:BCR) last announced its earnings results on Tuesday, July 26th. The company reported $2.54 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.07. C.R. Bard had a net margin of 9.20% and a return on equity of 48.43%. The firm earned $931.50 million during the quarter, compared to the consensus estimate of $915.22 million. During the same quarter in the previous year, the company posted $2.27 EPS. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis.
The business also recently announced a quarterly dividend, which will be paid on Friday, November 4th. Investors of record on Monday, October 24th will be issued a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $1.04 annualized dividend and a yield of 0.47%. C.R. Bard’s payout ratio is presently 24.24%.
In other C.R. Bard news, Chairman Timothy M. Ring sold 92,293 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $227.81, for a total transaction of $21,025,268.33. Following the transaction, the chairman now owns 145,876 shares of the company’s stock, valued at $33,232,011.56. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP John A. Deford sold 7,928 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $221.06, for a total value of $1,752,563.68. The disclosure for this sale can be found here. Corporate insiders own 0.97% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Standard Life Investments LTD acquired a new position in shares of C.R. Bard during the second quarter worth $241,642,000. Fundsmith LLP increased its position in shares of C.R. Bard by 24.7% in the second quarter. Fundsmith LLP now owns 2,197,626 shares of the company’s stock worth $516,220,000 after buying an additional 435,595 shares during the period. Bank of Montreal Can acquired a new position in shares of C.R. Bard during the second quarter worth $96,292,000. Vanguard Group Inc. increased its position in shares of C.R. Bard by 4.7% in the second quarter. Vanguard Group Inc. now owns 7,413,815 shares of the company’s stock worth $1,743,433,000 after buying an additional 335,276 shares during the period. Finally, BlackRock Fund Advisors increased its position in shares of C.R. Bard by 15.3% in the second quarter. BlackRock Fund Advisors now owns 2,175,495 shares of the company’s stock worth $511,589,000 after buying an additional 288,839 shares during the period. 87.90% of the stock is currently owned by hedge funds and other institutional investors.
About C.R. Bard
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.